

UC Irvine

UC Irvine Previously Published Works

Title

Arachidonic acid in cell signaling.

Permalink

<https://escholarship.org/uc/item/5dw7191z>

Journal

Current opinion in cell biology, 5(2)

ISSN

0955-0674

Author

Piomelli, D

Publication Date

1993-04-01

DOI

10.1016/0955-0674(93)90116-8

License

<https://creativecommons.org/licenses/by/4.0/> 4.0

Peer reviewed

Arachidonic acid in cell signaling

Daniele Piomelli

Institut National de la Santé et de la Recherche Médicale, Paris, France

Important advances have recently been made in our understanding of the arachidonic acid cascade. The molecular characterization of different forms of phospholipase A₂ indicates that multiple pathways are involved in the release of arachidonic acid evoked by physiological or pathological stimuli. Moreover, studies on the expression of enzymes that metabolize arachidonic acid reveal the potential participation of the eicosanoids in central aspects of cell regulation, such as control of mitogenesis. Finally, cloning of the first eicosanoid receptors is a major step towards elucidating the diverse cellular functions exerted by these bioactive lipids.

Current Opinion in Cell Biology 1993, 5:274–280

Introduction

The many cellular actions exerted by arachidonic acid (AA), a polyunsaturated fatty acid, are initiated by its release from membrane phospholipids and by its subsequent conversion into a family of biologically active metabolites, collectively called 'eicosanoids'. Some of the enzymatic pathways involved in AA release and metabolism are shown in Fig. 1, where I have summarized the results of studies that cannot be adequately described within the limits of this review. Here, I will review what I consider to be the most significant recent advances in three subject areas related to the AA cascade: the mechanism underlying release of AA; the molecular characterization of AA-metabolizing enzymes; and the cellular functions exerted by the eicosanoids.

Pathways of arachidonic acid release

Cytosolic, arachidonic acid specific phospholipase A₂

Phospholipase A₂ (PLA₂) catalyzes the hydrolytic cleavage of glycerophospholipid at the *sn*-2 position (where AA is most often esterified) yielding free fatty acid and lysophospholipid (Fig. 1). A high molecular weight (85.2 kDa) cytosolic phospholipase A₂ (cPLA₂), which selectively hydrolyzes AA-containing phospholipids, has been purified from several sources, and a full-length cDNA that encodes it has been isolated and sequenced [1–3,4•,5]. *In vitro*, purified cPLA₂ is active at concentrations of free Ca²⁺ (0.1–1 μmol/l) similar to those reached intracellularly during receptor-dependent Ca²⁺ responses, and prefers AA-containing phospholipids in natural membranes about 20-fold more than phospholipids containing other fatty acids.

Raising levels of Ca²⁺ from 100 to 300 nmol/l causes the association of recombinant cPLA₂ with membrane vesicles, suggesting that, in response to receptor-stimulated rises in Ca²⁺, cPLA₂ may translocate from the cytosol to the cell membrane, where both competent G proteins (see below) and phospholipid substrate are located [6•,7]. Ca²⁺-dependent translocation is probably mediated by a region in the amino-terminal portion of cPLA₂ that shows significant sequence homology with the constant region 2 of protein kinase C (PKC). This domain, which is thought to be involved in Ca²⁺-dependent binding of PKC to the membrane, is shared by other membrane-associated proteins including p65 (synaptotagmin), GTPase-activating protein and phosphoinositide-specific phospholipase C (PLC). By contrast, no sequence similarity appears to exist between cPLA₂ and any known low molecular weight (14 kDa) forms of PLA₂, which are not selective for phospholipids that contain AA [5].

Regulation of cPLA₂ activity by receptors, G proteins and protein phosphorylation

Several hormones, neurotransmitters, growth factors and cytokines evoke the rapid, receptor-dependent hydrolysis of AA-containing phospholipids. These include thyrotropin-releasing hormone [8•], serotonin acting at 5-HT₂ receptors [9], glutamate acting at metabotropic mGluR1 receptors [10•], basic fibroblast-derived growth factor [11] and α- and γ-interferons [12,13]. By contrast, neurotransmitters that do not stimulate AA release directly may amplify it when such release has been initiated by stimulating appropriate membrane receptors or by increasing intracellular Ca²⁺. These facilitatory mediators include the action of dopamine at D₂ receptors [14•],

Abbreviations

AA—arachidonic acid; CHO—Chinese hamster ovary; cPLA₂—cytosolic phospholipase A₂; DAG—diacylglycerol; EGF—epidermal growth factor; G protein—GTP-binding protein; PG—prostaglandin; PGHS—cyclo-oxygenase (prostaglandin G/H synthase); PKC—protein kinase C; PLC—phospholipase C.




Fig. 1. Release of AA from membrane phospholipids occurs by two main pathways. **(a)** Cleavage of the glycerophospholipid (PL) backbone at the *sn*-2 position, catalyzed by various forms of PLA₂, yields free AA and lysophospholipid. **(b)** Alternatively, activation of PLC forms DAG, which is subsequently hydrolyzed by DAG-lipase into free AA and monoacylglycerol (MAG). Further hydrolysis of MAG by MAG-lipase yields additional fatty acid and glycerol (not shown). Either pathway may be stimulated independently by occupation of G protein-linked membrane receptors (R₁ and R₂). **(c)** After release, free AA may be reincorporated into membrane PL. This reaction requires conversion of the fatty acid into arachidonoyl-coenzyme A (AA-CoA) by arachidonoyl-CoA synthetase, and its subsequent esterification by arachidonoyl-lysophospholipid transferase. **(d)** Alternatively, AA may be metabolized by one of three pathways: **(e)** PGHS catalyzes the conversion of AA into two reactive intermediates, PGG and PGH, which are, in turn, precursors of the prostaglandins, prostacyclin (PGI₂) and thromboxane (TXA₂); **(f)** lipoxygenases form hydroperoxyeicosatetraenoic acids (HPETE) as primary products, which can undergo a complex metabolism including reduction to corresponding hydroxyacids (HETE), or conversion into leukotrienes, epoxyhydroxides, etc.; **(g)** cytochrome P-450 catalyzes the conversion of AA into epoxyeicosatrienoic acids (EET), which are hydrolyzed to corresponding diols by epoxide hydrolase.

adenosine at A₁ [15•], norepinephrine at α_2 [16•], acetylcholine at muscarinic m₂ and m₄ [16•] and serotonin at 5-HT₁ [17•]. It is likely that stimulation of cPLA₂ activity mediates at least some of these responses. In agreement,

when Chinese hamster ovary (CHO) cells overexpressing cPLA₂ are stimulated with ATP or thrombin, release of AA is dramatically enhanced compared with wild-type CHO cells or cells overexpressing a low molecular weight form of PLA₂ [18••].

Beside Ca²⁺ levels, two additional elements appear to play important roles in the receptor-dependent activation of cPLA₂: an activated G protein and the activity of a serine protein kinase. In transfected CHO cells, pertussis toxin, which ADP-ribosylates and inhibits G proteins belonging to the G_i/G_o families, prevents both receptor-operated AA release [19] and facilitation of such release by stimulation of D₂ or 5-HT₁ receptors [14•,17•]. Pertussis toxin inhibits receptor-dependent stimulation of AA release in a similar manner in many other cell types [20], as well as facilitation of AA release produced by A₁ receptors in striatal glial cells [15•]. Phorbol esters enhance cPLA₂ activity in many tissues, whereas non-selective protein kinase inhibitors, such as staurosporine, inhibit it [16•,18••]. In addition, stimulation of cPLA₂ activity by ATP or phorbol ester in CHO cells, or by PDGF or EGF in Rat-2 cells, is accompanied by increased phosphorylation of cPLA₂ on a serine residue [18••]. The protein kinase responsible for phosphorylating cPLA₂ has been recently identified as mitogen-activated protein (MAP), which in turn may be activated by PKC-dependent protein phosphorylation [21]. Underscoring the differences existing between cPLA₂ and other types of PLA₂, the activity of membrane-bound PLA₂ in a preparation of rat brain synaptic endings is not affected by incubation with either phorbol esters or purified PKC [22•].

Low molecular weight forms of PLA₂

Based on primary structure, mammalian low molecular weight secreted and membrane-bound forms of PLA₂ (14 kDa) may be classified into two types, group I (PLA₂-I) and group II (PLA₂-II). Both groups may exert multiple cellular functions, participating in the non-selective release of fatty acids from phospholipids (including, beside AA, other substrates for oxydative metabolism, such as linoleic acid), in phospholipid remodelling (particularly important in preserving membrane integrity and in cell motility), or in a series of newly described actions mediated via high affinity membrane-binding sites, which have recently been the focus of several studies.

A high affinity binding site for PLA₂-I has been characterized in various cell types [23], and is thought to mediate the effects of PLA₂-I on proliferation of Swiss 3T3 fibroblasts and on stimulation of migration of embryonic smooth muscle and contraction of isolated cerebral arteries [24,25,26•]. It is not known whether the phospholipid-hydrolyzing activity of PLA₂-I is crucial for these actions. Like PLA₂-I, PLA₂-II may also be secreted from cells, and bind to specific membrane receptors. Several agents have been shown to stimulate expression and secretion of PLA₂-II, in parallel with AA release and metabolism. These include pro-inflammatory factors, such as tumor necrosis factor, interleukin I and lipopolysaccharide. By contrast, anti-inflammatory gluco-

corticoids inhibit expression of PLA₂-II, suggesting that regulation of expression and secretion of this lipase may play a role in the pathogenesis of inflammation [27•,28•].

Phospholipase C/diacylglycerol lipase

Activation of PLA₂ provides a direct pathway of AA release. Alternatively, release may be initiated by the activation of phosphoinositide-specific PLC, which cleaves the phospholipid at the phosphate ester bond producing 1,2-diacylglycerol (DAG). This intermediate is in turn broken down by a DAG-lipase to yield free fatty acid and monoacylglycerol (Fig. 1). The PLC/DAG-lipase pathway, originally described in blood platelets, has now been unequivocally shown to mediate bradykinin-induced release of AA in dorsal root ganglion neurons in primary culture [29••].

Molecular characterization of enzymes that metabolize arachidonic acid

After release, free AA has several possible fates. It can diffuse out of the cell. Alternatively, it can be either converted into arachidonoyl-coenzyme A and reincorporated into phospholipids, or metabolized. Most enzymes involved in the metabolism of AA (cyclooxygenase, PGD synthase, PGF synthase, 5-lipoxygenase, leukotriene A₄ hydrolase, 15-lipoxygenase and 12-lipoxygenase) have been purified from various sources, and cDNAs encoding them have been isolated and characterized. The interested reader is referred to a recent review [30••], to which only a few developments need to be added here.

Cyclooxygenase

Cyclooxygenase (prostaglandin G/H synthase, PGHS) catalyzes the stepwise conversion of AA into the reactive intermediates PGG and PGH, which are in turn the precursors of prostaglandins, prostacyclin and thromboxanes. Two cDNAs encoding PGHS have been isolated. One, obtained by screening cDNA libraries of sheep seminal vesicles, hybridizes with a 2.8–3.0 kb mRNA on northern blots [30••]. This mRNA may undergo alternative splicing, resulting in a transcript that is 111 base pairs shorter [31]. An additional 4.1 kb cDNA encoding for a PGHS-related protein has been recently cloned, and shown to confer PGHS activity to transfected cells. Unlike the 2.8 kb PGHS mRNA, levels of the 4.1 kb mRNA rapidly increase in human monocytes stimulated with pro-inflammatory agents, such as interleukin 1 β , and decrease in monocytes stimulated with anti-inflammatory agents, such as dexamethasone. The results suggest that induction of this transcriptionally regulated PGHS species, termed glucocorticoid-regulated inflammatory (gri) PGHS, may participate in the inflammatory response [32,33••]. The functions of griPGHS are unlikely to be limited to inflammation, however. Evidence indicates that griPGHS is identical to TIS10, the product of a primary response gene whose ex-

pression is superinduced by the mitogenic phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, in a cell type restricted fashion [34••,35]. It is known that mitogenic signals induce a transient enhancement of prostaglandin release, and the discovery that a primary response gene encodes an active PGHS provides further support for a role of AA metabolism in the regulation of cell division (see below).

Cellular actions of the eicosanoids

The eicosanoids may act both as intracellular second messengers and as local mediators (autacoids): like second messengers, they may modify the activity of intracellular enzymes and ion channels; like local mediators, the eicosanoids may be released outside the cell of origin, and act on neighbouring cells by binding to high-affinity membrane receptors.

Regulation of ion channels and secretion

Both free AA and its metabolites can influence the activity of many membrane ion channels, either directly or by regulating intracellular protein kinases. Two brief reviews on this subject may be consulted for studies published before 1991 [36•,37•].

Recent reports support the involvement of lipoxygenase metabolites of AA in the activation of K⁺ channels in a variety of cells ranging from molluscan neurons to mammalian platelets [38•–40•], and in the modulation of hormone and neurotransmitter secretion [41•,42•,43]. In secretory cells, including neurons, the activation of K⁺ channels, by decreasing cell excitability, is expected to result in reduced Ca²⁺-dependent secretion. In agreement, in a preparation of synaptic nerve endings, 12-lipoxygenase metabolites of AA inhibit Ca²⁺-dependent glutamate release, possibly through activation of K⁺ channels [41•]. In addition to this effect, lipoxygenase products may regulate secretion by inhibiting Ca²⁺/calmodulin-dependent protein phosphorylation [37•]. Ca²⁺/calmodulin-dependent protein kinase II plays an important role in the regulation of neurosecretion. Experiments with isolated pancreatic islets suggest that free AA, generated by physiological concentrations of glucose, may be part of a negative feedback loop that prevents excess insulin secretion by inhibiting Ca²⁺/calmodulin-dependent protein kinase II activity [42•].

The actions of AA on neurosecretion are not limited to the inhibitory effects described above. Evidence indicates that AA and other polyunsaturated fatty acids may participate in certain forms of long-term potentiation, a model of synaptic plasticity and information storage that is thought to require, at least partly, enhanced release of glutamate from presynaptic terminals [44]. It was recently shown that stimulation of presynaptic glutamate receptors may enhance Ca²⁺-dependent release of glutamate if free AA is also provided at low micromolar

concentrations [45••]. It is not known for certain where AA comes from; one suggestion is that it may be generated by stimulating postsynaptic glutamate receptors, and diffuse as a 'retrograde messenger' to the presynaptic terminal [44]. Other effects of AA also support a participation of this fatty acid in long-term potentiation, for example, its ability to potentiate ion currents at the glutamate N-methyl-D-aspartate receptor channel, which is central to the expression of long-term potentiation [46].

Modulation of Na⁺/K⁺ ATPase activity

The activity of Na⁺/K⁺ ATPase supplies the driving force for transcellular transport of electrolytes and organic solutes, playing a central role in the reabsorptive capacity of the kidney and in the maintenance of ion gradients in neural cells. Recent studies suggest the eicosanoids may participate in regulating Na⁺/K⁺ ATPase. Metabolites of AA via the epoxygenase (cytochrome P450) pathway are potent inhibitors of Na⁺/K⁺ ATPase activity in kidney tissue [47•]. Other metabolic pathways may also be involved, however [48–50]. For example, the inhibition of Na⁺/K⁺ ATPase activity produced by interleukin-1 in kidney collecting duct may be mediated by the prostaglandin, PGE₂. In agreement, interleukin-1 stimulates formation of PGE₂, while application of exogenous PGE₂ inhibits Na⁺/K⁺ ATPase activity. Moreover, PGHS blockers prevent Na⁺/K⁺ ATPase inhibition induced by interleukin-1 [48]. The actions of the eicosanoids on Na⁺/K⁺ ATPase may not be limited to the kidney, as AA also affects the enzyme activity in brain tissue [51].

Regulation of cell proliferation

Stimulation of mitogenesis by growth factors is accompanied by marked changes in lipid turnover, including release and metabolism of AA. As discussed above, the primary response gene, *TIS10*, which can be superinduced by mitogenic stimuli, encodes an active PGHS, suggesting an involvement of prostaglandins in mitogenic control [34••]. Several studies lend further support to this idea. For example, in BALB/c3T3 fibroblasts, epidermal growth factor (EGF) stimulates formation of PGE₂ and PGF_{2α}. These prostaglandins, in turn, enhance EGF-dependent DNA synthesis and *c-myc* expression [52]. Moreover, PGHS inhibitors prevent EGF-induced mitogenesis in BALB/c3T3 cells, an effect which may be overcome by the addition of exogenous prostaglandins [52]. Non-PGHS metabolites of AA may also play a role in modulating proliferation induced by various factors, including EGF in Syrian hamster embryo cells and rat mesangial cells [53–55], and angiotensin II in bovine adrenocortical cells [56]. The enzymatic pathways involved in these responses are not well characterized yet, but pharmacological experiments suggest that either lipoxygenases (both 12- and 15-lipoxygenase) or cytochrome P450 may participate. Interestingly, AA may not be the only substrate

utilized. Because substrate requirement is less strict for lipoxygenases than for PGHS, other polyunsaturated fatty acids liberated by PLA₂ activation, such as linoleic acid, may be converted into products that modulate mitogenesis [53].

Eicosanoid receptors

Many transcellular actions of the eicosanoids are mediated by specific membrane receptors. A high-affinity receptor for thromboxane A₂ (TXA₂) was recently purified to apparent homogeneity, and its cDNA was cloned and characterized [57••]. The cDNA encodes a protein of 343 amino acids with seven putative transmembrane domains, which is linked to activation of phosphatidylinositol turnover and Ca²⁺ mobilization when expressed in *Xenopus* oocytes. Subsequently, polymerase chain reaction based on the sequence of this TXA₂ receptor has revealed a cDNA clone encoding a prostaglandin E receptor EP₃ subtype, and shown it to consist of 365 amino acids with seven putative transmembrane domains. When expressed in CHO cells, the EP₃ receptor is linked to G_i-mediated inhibition of adenylyl cyclase activity [58].

Conclusions

The last 2 years have helped in clarifying several longstanding problems related to AA-mediated signaling. The central position of cPLA₂ in receptor-operated AA release is now beginning to be appreciated, as are the different roles played by free Ca²⁺, G proteins and protein phosphorylation in regulating activity of this enzyme. At the same time, the importance of additional pathways of AA release (low molecular weight forms of PLA₂, PLC/DAG-lipase) has been reinforced. This emerging diversity in the control of AA release underscores, on the one hand, the multiplicity of functions of this signaling cascade, and indicates, on the other, potential sites of action for novel therapeutic agents, directed at specific aspects of AA-related pathologies. Likewise, molecular biological studies are revealing the existence, not only of important diversities at the level of AA-metabolizing enzymes, which were once thought to be single entities, but also of exciting differences in expression and function of these various enzyme isoforms.

Acknowledgements

I thank Dr Lih-Ling Lin (Genetics Institute, Boston, Massachusetts, USA) for communicating results before publication and the National Alliance for Research on Schizophrenia and Depression for financial support.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. GRONICH JH, BONVENTRE JV, NEMENOFF RA: Purification of a High-Molecular-Mass Form of Phospholipase A₂ from Rat Kidney Activated at Physiological Calcium Concentrations. *Biochem J* 1990, 271:37–43.
2. CLARK JD, MILONA N, KNOPF JL: Purification of a 110-Kilodalton Cytosolic Phospholipase A₂ from the Human Monocytic Line U937. *Proc Natl Acad Sci USA* 1990, 87:7708–7712.
3. WIJKANDER J, SUNDLER G: An 100-kDa Arachidonate-Mobilizing Phospholipase A₂ in Mouse Spleen and the Macrophage Cell Line J774. *Eur J Biochem* 1991, 202:873–880.
4. KRAMER RM, ROBERTS EF, MANETTA J, PUTNAM JE: The Ca²⁺-Sensitive Cytosolic Phospholipase A₂ is a 100-kDa Protein in Human Monoblast U937 Cells. *J Biol Chem* 1991, 266:5268–5272.

This paper and [1–3] describe the purification of a high molecular weight form of PLA₂ (cPLA₂) activated by physiological concentrations of Ca²⁺ and characterized by a high selectivity for AA-containing phospholipids.

5. SHARP JD, WHITE DL, CHIOU XG, GOODSON T, GAMBOA GC, MCLURE D, BURGETT S, HOSKIN J, SKATRUD PL, SPORTSMAN JR, ET AL: Molecular Cloning and Expression of Human Ca²⁺-Sensitive Cytosolic Phospholipase A₂. *J Biol Chem* 1991, 266:14850–14853.
6. CLARK JD, LIN L-L, KRIZ RW, RAMESHA CS, SULTZMAN LA, LIN AY, MILONA N, KNOPF JL: A Novel Arachidonic Acid-Selective Cytosolic PLA₂ Contains a Ca²⁺-Dependent Translocation Domain with Homology to PKC and GAP. *Cell* 1991, 65:1043–1051.

Describes the molecular cloning and expression of human and rat cPLA₂ gene, and demonstrates the protein's Ca²⁺-dependent translocation from cytosol to membrane; identifies sequence homologies with the constant region 2 of PKC, as well as with the Ca²⁺/phospholipid-binding domains of synaptotagmin and GTPase-activating protein. See [5].

7. CHANNON JY, LESLIE CC: A Calcium-Dependent Mechanism for Associating a Soluble Arachidonoyl-Hydrolyzing Phospholipase A₂ with Membrane in the Macrophage Cell Line RAW 264.7. *J Biol Chem* 1990, 265:5409–5413.
8. JUDD AM, MACLEOD RM: Thyrotropin-Releasing Hormone and Lysine-Bradykinin Stimulate Arachidonate Liberation from Rat Anterior Pituitary Cells through Different Mechanisms. *Endocrinology* 1992, 131:1251–1260.

Although thyrotropin-releasing hormone and lysine-bradykinin both stimulate AA release from pituitary cells, they show marked differences in the time course and Ca²⁺-dependence of their responses, suggesting the participation of distinct mechanisms of release.

9. FELDER CC, KANTERMAN RY, MA AL, AXELROD J: Serotonin Stimulates Phospholipase A₂ and the Release of Arachidonic Acid in Hippocampal Neurons by a Type 2 Serotonin Receptor that is Independent of Inositolphospholipid Hydrolysis. *Proc Natl Acad Sci USA* 1990, 87:2187–2191.
10. ARAMORI I, NAKANISHI S: Signal Transduction and Pharmacological Characteristics of a Metabotropic Glutamate Receptor, mGluR1, in Transfected CHO Cells. *Neuron* 1992, 8:757–765.

The results of this and other studies (e.g. [17*]), showing that a single receptor subtype may be coupled to multiple intracellular signaling systems, raise the intriguing question of how parallel signals operating at a single receptor may be co-ordinated and integrated within a cell.

11. FAFEUR V, JIANG ZP, BÖHLEN P: Signal Transduction by bFGF, but not TGFβ1, Involves Arachidonic Acid Metabolism in Endothelial Cells. *J Cell Physiol* 1991, 149:277–283.

12. HANNIGAN GE, WILLIAMS BRG: Signal Transduction by Interferon-α through Arachidonic Acid Metabolism. *Science* 1991, 251:204–207.

13. PONZONI M, MONTALDO PG, CORNAGLIA-FERRARIS P: Stimulation of Receptor-Coupled Phospholipase A₂ by Interferon-γ. *FEBS Lett* 1992, 310:17–21.

14. PIOMELLI D, PILON C, GIROS B, SOKOLOFF P, MARTRES MP, SCHWARTZ JC: Dopamine Activation of the Arachidonic Acid Cascade as a Basis for D₁/D₂ Receptor Synergism. *Nature* 1991, 353:164–167.

The experiments described in this paper and [15•–17•] demonstrate that certain neurotransmitter receptors, including D₂ dopaminergic and α₂ adrenergic, may enhance the release of AA evoked by elevating intracellular Ca²⁺ levels. A G protein belonging to the G_i/G_o families, sensitive to pertussis toxin, appears to be involved in this facilitatory action.

15. EL-ETR M, MARIN P, TENCÉ M, DELUMEAU JC, CORDIER J, GLOWINSKI J, PRÉMONT J: 2-Chloroadenosine Potentiates the α₁-Adrenergic Activation of Phospholipase C through a Mechanism Involving Arachidonic Acid and Glutamate in Striatal Astrocytes. *J Neurosci* 1992, 4:1363–1369.

See [14•].

16. FELDER CC, WILLIAMS HL, AXELROD J: A Transduction Pathway Associated with Receptors Coupled to the Inhibitory Guanine Nucleotide Binding Protein Gi that Amplifies ATP-Mediated Arachidonic Acid Release. *Proc Natl Acad Sci USA* 1991, 88:6477–6480.

See [14•].

17. RAYMOND JR, ALBERS FJ, MIDDLETON JP: Functional Expression of Human 5-HT_{1A} Receptors and Differential Coupling to Second Messengers in CHO Cells. *Naunyn-Schmiedberg's Arch Pharmacol* 1992, 346:127–137.

See [14•].

18. LIN LL, LIN AY, KNOPF JL: Cytosolic Phospholipase A₂ is Coupled to Hormonally Regulated Release of Arachidonic Acid. *Proc Natl Acad Sci USA* 1992, 89:6147–6151.

CHO cells overexpressing cPLA₂ show a much greater release of AA in response to receptor stimulation than wild type cells. Phosphorylation on a serine residue accompanies receptor stimulation of cPLA₂, while staurosporine (a protein kinase inhibitor) prevents both phosphorylation and activation of cPLA₂. This paper provides important evidence in favour of a role for cPLA₂ in receptor-operated AA release.

19. GUPTA SK, DIEZ E, HEASLEY LE, OSAWA S, JOHNSON GL: A G Protein Mutant that Inhibits Thrombin and Purinergic Receptor Activation of Phospholipase A₂. *Science* 1990, 249:662–666.

20. BURCH RM: G Protein Regulation of Phospholipase A₂. *Mol Neurobiol* 1989, 3:155–171.

21. LIN L-L, WARTMANN M, LIN AY, KNOPF JL, SETH A, DAVIS R: cPLA₂ is Phosphorylated and Activated by MAP Kinase. *Cell* 1993, 72:269–278.

22. PIOMELLI D, GREENGARD P: Bidirectional Control of Phospholipase A₂ Activity by Ca²⁺/Calmodulin-Dependent Protein Kinase II, cAMP-Dependent Protein Kinase, and Casein Kinase II. *Proc Natl Acad Sci USA* 1991, 88:6770–6774.

In intact rat brain synaptic terminals (synaptosomes), membrane-bound, non-AA-specific PLA₂ activity is selectively inhibited by membrane depolarization and Ca²⁺ ionophores through activation of Ca²⁺/calmodulin-dependent protein kinase II. By contrast, cAMP-dependent protein kinase and casein kinase II potentiate PLA₂ activity, whereas PKC has no effect.

23. HANASAKI K, ARITA H: Characterization of a High Affinity Binding Site for Pancreatic-Type Phospholipase A₂ in the Rat. Its Cellular and Tissue Distribution. *J Biol Chem* 1992, 267:6414–6420.

24. ARITA H, HANASAKI K, NAKANO T, OKA S, TERAOKA H, MATSUMOTO K: Novel Proliferative Effect of Phospholipase A₂ in Swiss 3T3 Cells via Specific Binding Site. *J Biol Chem* 1991, 266:19139–19141.

25. KANEMASA T, HANASAKI K, ARITA H: **Migration of Vascular Smooth Muscle Cells by Phospholipase A₂ via Specific Binding Sites.** *Biochim Biophys Acta* 1992, 1125:210–214.

26. NAKAJIMA M, HANASAKI K, UEDA M, ARITA H: **Effect of Pancreatic Type Phospholipase A₂ on Isolated Porcine Cerebral Arteries via Its Specific Binding Sites.** *FEBS Lett* 1992, 309:261–264.

This paper and [23–25] report the characterization of high-affinity binding sites for extracellular PLA₂-I in the membrane of several tissues and cells, as well as some of their possible biological effects. The results support the possibility that secreted forms of PLA₂ may act as extracellular mediators in normal or pathological conditions and raise the question as to whether phospholipase activity participates in these receptor-mediated actions of PLA₂-I.

27. SCHALKWIJK C, PFEELSCHIFTER J, MÄRKI F, VAN DEN BOSCH H: **Interleukin-1 β - and Forskolin-Induced Synthesis and Secretion of Group II Phospholipase A₂ and Prostaglandin E₂ in Rat Mesangial Cells is Prevented by Transforming Growth Factor- β 2.** *J Biol Chem* 1992, 267:8846–8851.

See [28*].

28. OKA S, ARITA H: **Inflammatory Factors Stimulate Expression of Group II Phospholipase A₂ in Rat Cultured Astrocytes. Two Distinct Pathways of the Gene Expression.** *J Biol Chem* 1991, 266:9956–9960.

This paper and [27*] address the regulation of expression and release of PLA₂-II from cultured cells. They demonstrate that pro-inflammatory factors enhance levels of PLA₂-II protein and mRNA levels, whereas anti-inflammatory factors decrease them.

29. ALLEN AC, GAMMON CM, OUSLEY AH, MCCARTHY KD, MORELL P: **Bradykinin Stimulates Arachidonic Acid Release through the Sequential Actions of an sn-1 Diacylglycerol Lipase and a Monoacyl Glycerol Lipase.** *J Neurochem* 1992, 58:1130–1139.

The first unequivocal demonstration that, in neuronal cells, bradykinin receptors stimulate AA release via activation of PLC, followed by hydrolysis of DAG mediated by DAG-lipase.

30. SIGAL E: **The Molecular Biology of Mammalian Arachidonic Acid Metabolism.** *Am J Physiol* 1991, 260:L13–L28.

This is the best updated reference on the cloning and molecular characterization of AA-metabolizing enzymes. This review cites 128 papers, including many published in 1990.

31. DIAZ A, REGINATO AM, JIMENEZ SA: **Alternative Splicing of Human Prostaglandin G/H Synthase mRNA and Evidence of Differential Regulation of the Resulting Transcripts by Transforming Growth Factor β ₁, Interleukin 1 β , and Tumor Necrosis Factor α .** *J Biol Chem* 1991, 267:10816–10822.

32. O'BANION MK, SADOWSKI HB, WINN VD, YOUNG DA: **A Serum- and Glucocorticoid-Regulated 4-Kilobase mRNA Encodes a Cyclooxygenase-Related Protein.** *J Biol Chem* 1991, 266:23261–23267.

33. O'BANION MK, WINN VD, YOUNG DA: **cDNA Cloning and Functional Activity of a Glucocorticoid-Regulated Inflammatory Cyclooxygenase.** *Proc Natl Acad Sci USA* 1992, 89:4888–4892.

See [34**].

34. KUJUBU DA, FLETCHER BS, VARNUM BC, LIM RW, HERSCHMAN HR: **TIS10, a Phorbol Ester Tumor Promoter-Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homologue.** *J Biol Chem* 1991, 266:12866–12872.

This paper and [33**] describe the results of two independent groups, which converge in demonstrating the identity of the *PGHS* gene with *TIS10*, a primary response gene superinduced by phorbol ester in a highly cell-specific fashion.

35. KUJUBU DA, HERSCHMAN HR: **Dexamethasone Inhibits Mitogen Induction of the TIS10 Prostaglandin Synthase/Cyclooxygenase Gene.** *J Biol Chem* 1992, 267:7991–7994.

36. ORDWAY RW, SINGER JJ, WALSH JV: **Direct Regulation of Ion Channels by Fatty Acids.** *Trends Neurosci* 1991, 14:96–100. Focus on the ability of polyunsaturated fatty acids, including AA, to modulate the activity of membrane ion channels directly (that is, without metabolism or intervention of other signaling pathways). See [37*].

37. PIOMELLI D, GREENGARD P: **Lipoxygenase Metabolites of Arachidonic Acid in Neuronal Transmembrane Signalling.** *Trends Pharmacol Sci* 1990, 11:367–373.

Along with [36*], this review also deals with ion channel regulation by PLA₂-derived second messengers. Here, the authors describe the possible roles of lipoxygenase metabolites of AA in neuronal signal transduction, suggested by their actions on ion channel and protein kinase activities.

38. BAHLS FH, RICHMOND JE, SMITH WL, HAYDON PG: **A Lipoxygenase Pathway of Arachidonic Acid Metabolism Mediates FMRamide Activation of a Potassium Current in an Identified Neuron of Helisoma.** *Neurosci Lett* 1992, 138:165–168.

See [40*].

39. NAKAJIMA T, SUGIMOTO T, KURACHI Y: **Platelet-Activating Factor Activates Cardiac G_K via Arachidonic Acid Metabolites.** *FEBS Lett* 1991, 289:239–243.

See [40*].

40. MARGALIT A, LIVNE AA: **Lipoxygenase Product Controls the Regulatory Volume Decrease of Human Platelets.** *Platelets* 1991, 2:207–214.

This paper and [38*39*] provide three different examples of K⁺ channel modulation by lipoxygenase-derived eicosanoids. In identified neurons of the mollusc, *Helisoma*, a lipoxygenase product may act as second messenger in the modulation of K⁺ channel activity by the inhibitory tetrapeptide, FMRF-amide. In cardiac myocytes, metabolites of AA formed through the 5-lipoxygenase pathway may mediate the stimulation of muscarinic K⁺ channels caused by application of platelet-activating factor. Finally, a 12-lipoxygenase product may participate in the osmotic volume control in human platelets, by regulating permeability to K⁺ ions.

41. FREEMAN EJ, DAMRON DS, TERRIAN DM, DORMAN RV: **12-Lipoxygenase Products Attenuate the Glutamate Release and Ca²⁺ Accumulation Evoked by Depolarization of Hippocampal Mossy Fiber Nerve Endings.** *J Neurochem* 1991, 56:1079–1082.

This paper describes one of the two distinct mechanisms that may underlie the modulatory effects of AA and its metabolites on secretion (see [42*]). In a preparation of synaptic endings, the 12-lipoxygenase product, 12-HETE, may reduce Ca²⁺-dependent glutamate release through activation of K⁺ channels and reduction of cell excitability.

42. LANDT M, EASOM RA, COLCA JR, WOLF BA, TURK J, MILLS LA, MCDANIEL ML: **Parallel Effects of Arachidonic Acid on Insulin Secretion, Calmodulin-Dependent Protein Kinase Activity and Protein Kinase C Activity in Pancreatic Islets.** *Cell Calcium* 1992, 13:163–172.

This paper describes one of the two distinct mechanisms that may underlie the modulatory effects of AA and its metabolites on secretion (see [41*]). In pancreatic islets, AA may prevent glucose-induced insulin secretion through inhibition of type II Ca²⁺/calmodulin-dependent protein kinase activity. The mechanisms documented in this paper and [41*] are not mutually exclusive, however, and they may cooperate within the same cell.

43. BOURDEAU A, SOUBERBIELE J-C, BONNET P, HERVIAUX P, SACHS C, LIEBERHERR M: **Phospholipase-A₂ Action and Arachidonic Acid Metabolism in Calcium-Mediated Parathyroid Hormone Secretion.** *Endocrinology* 1992, 130:1339–1344.

44. FAZELI MS: **Synaptic Plasticity: on the Trail of the Retrograde Messenger.** *Trends Neurosci* 1992, 15:115–117.

45. HERRERO I, MIRAS-PORTUGAL MT, SANCHEZ-PRIETO JS: **Positive Feedback of Glutamate Exocytosis by Metabotropic Presynaptic Receptor Stimulation.** *Nature* 1992, 360:163–166.

In a preparation of presynaptic terminals from rat brain, the stimulation of metabotropic glutamate receptors markedly enhances glutamate release, provided that a relatively low (2 μ mol/l) concentration of free AA is present. Because glutamate evokes AA release in cultured neu-

rons, the results suggest that AA, liberated at the postsynaptic level, may act presynaptically by enabling the potentiating effect of metabotropic receptors on glutamate release.

46. MILLER B, SARANTIS M, TRAYNELIS SF, ATTWELL D: Potentiation of NMDA Receptor Currents by Arachidonic Acid. *Nature* 1992, 355:722-725.
47. MCGIFF JC: Cytochrome P-450 Metabolism of Arachidonic Acid. *Annu Rev Pharmacol Toxicol* 1991, 31:339-369.
Exhaustive review on the biochemistry, physiology and pharmacology of the cytochrome P-450 AA pathway, updated to 1990.
48. ZEIDEL ML, BRADY HR, KOHAN DE: Interleukin-1 Inhibition of Na⁺/K⁺ ATPase in Inner Medullary Collecting Duct: Role of PGE₂. *Am J Physiol* 1991, 261:F1013-F1016.
49. SATOH T, COHEN HT, KATZ AI: Intracellular Signaling in the Regulation of Renal Na-K-ATPase. I. Role of Cyclic AMP and Phospholipase A₂. *J Clin Invest* 1992, 89:1496-1500.
50. TAUB ML, WANG Y, YANG I-S, FIORELLA P, LEE SM: Regulation of the Na,K-ATPase Activity of Madin-Darby Canine Kidney Cells in Defined Medium by Prostaglandin E₁ and 8-Bromocyclic AMP. *J Cell Physiol* 1992, 151:337-346.
51. FREEMAN EJ, TERRIAN DM, DORMAN RV: Presynaptic Facilitation of Glutamate Release from Isolated Hippocampal Mossy Fiber Nerve Endings by Arachidonic Acid. *Neurochem Res* 1990, 15:743-750.
52. HANDLER JA, DANILOWICZ RM, ELING TE: Mitogenic Signaling by Epidermal Growth Factor (EGF), but not Platelet-Derived Growth Factor, Requires Arachidonic Acid Metabolism in BALB/c3T3 Cells. *J Biol Chem* 1990, 265:3669-3673.
53. GLASGOW WC, ELING TE: Epidermal Growth Factor Stimulates Linoleic Acid Metabolism in BALB/c3T3 Fibroblasts. *Mol Pharmacol* 1990, 38:503-510.
54. GLASGOW WC, AFSHARI CA, BARRETT JC, ELING TE: Modulation of the Epidermal Growth Factor Mitogenic Response by Metabolites of Linoleic and Arachidonic Acid in Syrian Hamster Embryo Fibroblasts. Differential Effects in Tumor Suppressor Gene(+) and (-) Phenotypes. *J Biol Chem* 1992, 267:10771-10779.
55. SELLMAYER A, UEDELHOVEN WM, WEBER PC, BONVENTRE JV: Endogenous Non-Cyclooxygenase Metabolites of Arachidonic Acid Modulate Growth and mRNA Levels of Immediate-Early Response Genes in Rat Mesangial Cells. *J Biol Chem* 1991, 266:3800-3807.
56. NATARAJAN R, GONZALES N, HORNSBY PJ, NADLER J: Mechanism of Angiotensin II-Induced Proliferation in Bovine Adrenocortical Cells. *Endocrinology* 1992, 131:1174-1180.
57. HIRATA M, HAYAISHI Y, USHUKUBI F, YOKOTA Y, KAGEYAMA R, NAKANISHI S, NARUMIYA S: Cloning and Expression of cDNA for a Human Thromboxane A₂ Receptor. *Nature* 1991, 349:617-620.
Molecular cloning and characterization of the TXA₂ receptor, the first eicosanoid receptor characterized at the molecular level. This study sets the stage for the isolation of related receptor molecules, such as that described by Sugimoto and colleagues [58].
58. SUGIMOTO Y, NAMBA T, HONDA A, HAYAISHI Y, NEGISHI M, ICHIKAWA A, NARUMIYA S: Cloning and Expression of a cDNA for Mouse Prostaglandin E Receptor EP₃ Subtype. *J Biol Chem* 1992, 267:6463-6466.

D Piomelli, Unité de Neurobiologie et Pharmacologie de l'INSERM (U.109), 2ter rue d'Alésia, Paris 75014, France.